stockrowJazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −280.5%
- Free cash flow
- −60.4%
- Total debt
- +3.88%
Quarter to September 2026, against a year earlier
Follow JAZZ
Alert me
Jazz Pharmaceuticals PLC (JAZZ) Gross margin
Jazz Pharmaceuticals PLC's gross margin over the twelve months to 30 September 2026 was 89.1%, up 0.9 percentage points from fiscal 2025 (88.2%). Over the past ten years it has ranged from 85.2% (fiscal 2022) to 94.1% (fiscal 2019); the current reading is higher than 27% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 88.2% | (0.84) |
| FY2024 | 89.1% | 0.41 |
| FY2023 | 88.6% | 3.41 |
| FY2022 | 85.2% | (0.53) |
| FY2021 | 85.8% | (7.94) |
| FY2020 | 93.7% | (0.38) |
| FY2019 | 94.1% | 0.51 |
| FY2018 | 93.6% | 0.38 |
| FY2017 | 93.2% | 0.27 |
| FY2016 | 92.9% | 0.66 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 91.1% | 0.73 |
| Jun 2026 | 90.4% | 2.92 |
| Mar 2026 | 87.5% | 0.26 |
| Dec 2025 | 87.2% | (1.36) |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| SMMT Summit Therapeutics PLC compare | 100.0% |
| KYMR Kymera Therapeutics, Inc. compare | 100.0% |
| EXEL Exelixis, Inc. compare | 96.3% |
| BBIO BridgeBio Pharma, Inc. compare | 94.3% |
| ASND Ascendis Pharma A/S compare | 91.3% |
| JAZZ Jazz Pharmaceuticals PLC | 89.1% |
| HALO Halozyme Therapeutics, Inc. compare | 82.3% |
| BMRN BioMarin Pharmaceutical Inc. compare | 76.0% |
| TECH Bio-Techne Corp compare | 65.8% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on JAZZ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement